Reports Q4 revenue $653,000, consensus $580,000. "2022 was a momentous year for Prometheus and the IBD community, highlighted by the positive readout in both PRA023 Phase 2 studies in UC and CD, which we believe set a new standard in IBD by combining high efficacy and favorable safety results," said Mark McKenna, chairman and CEO of Prometheus Biosciences. "We continue to believe that PRA023 is a potential best-in-class and first-in-class therapeutic candidate for IBD and we intend on carrying this momentum into 2023 by advancing PRA023 into Phase 3 studies."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RXDX:
- Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
- Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)
- Looking for Powerful Healthcare Stocks? These 5 Made Enormous Profit in 2022
- Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
- Prometheus, Roivant TL1A data look ‘highly competitive,’ says Piper
